

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
Evan B. Dreyer

Serial No: Not yet assigned

Filed: Herewith

For: CALCIUM BLOCKERS TO TREAT
PROLIFERATIVE
VITREORETINOPATHY

Examiner: Not yet assigned
(Zohreh A. Fay in parent)

Group Art Unit: Not yet assigned
(1614 in parent)

Confirmation No. Not yet assigned
(1275 in parent)

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Box Patent Application
Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Pursuant to 37 CFR § 1.98(d), copies of any patent publication or other information are not required to be provided if they were previously cited by or submitted to the Patent and Trademark Office in a prior application to which priority is claimed under 35 USC § 120.

BEST AVAILABLE COPY

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Respectfully submitted,



Brent A. Johnson, Ph.D.
Registration No. 51,851
Attorney of Record
Telephone: 714/246-4348
Telecopier: 714/246-4249

Brent A. Johnson, Ph.D. (T2-7H)
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612


CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Information Disclosure and the documents referred to as enclosed herein are being deposited with the United States Postal Service on May 12, 2003 in an envelope as "Express Mail Post Office To Addressee" mailing label number EL385560942US with sufficient postage for Express Mail addressed to MAIL STOP: PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Date: May 12, 2003

Susan Bartholomew

Name of person mailing paper



Signature of person mailing paper

BEST AVAILABLE COPY

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17322CON2(AP)	SERIAL NO.: Not Assigned
APPLICANT: Dreyer	TITLE: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY
FILING DATE: Submitted herewith	GROUP: Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,431,907	7/1995	Abelson et al			
	AB	5,623,051	4/1997	Caterall et al			
	AC	5,710,165	1/1998	Kapin et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Machamer (1978) British J. Ophthal. 62:737
	CB	Hilton et al (1983) Ophthalmology 90:121
	CC	Sommer et al , "Glutamate receptor channels: novel properties and new clones", Trends Pharmacological Sciences 13: 291-296 (1992)
	CD	Nakanishi, "Molecular Diversity of glutamate receptors and implications for brain function", Science 248: 597-603 (1992)
	CE	Karschian et al, J. Physiol. 418: 379-396 (1989)
	CF	Watkins et al, Trends in Pharmacological Sci. 11: 25, 1990
	CG	Bean, Annual Rev. Physiol. 51: 367-384 (1989)
	CH	Hess, Annual Rev. Neurosci. 13: 337-356 (1990)
	CI	Kiumura et al, Human Gene Therapy, 7: 799-808 (1996)
	CJ	Sakamoto et al, Ophthalmology 102: 1417-1421 (1995)
	CK	Handa et al, Experimental Eye Research 62: 689-696 (1996)
	CL	Berger et al 37: 2318-2325 (1996)
	CM	de Souza et al, Ophthalmologica 209: 212-216 (1995)
	CN	Nakagawa et al, Ophthalmology & Visual Science 36: 2388-2395 (1995)
	CO	Steinhorst et al, Archive for Clinical & Experimental Ophthalmology 232: 347-354 (1994)

BEST AVAILABLE COPY

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.